Drug recall · July 1, 2020
Metformin Hydrochloride Extended-Release Tablets recall
Why: CGMP Deviations: FDA analysis detected N-Nitrosodimethylamine (NDMA) impurity above the acceptable intake level
Class II: could cause temporary or reversible health problems; serious harm is remote.
The recall
- Product
Metformin Hydrochloride Extended-Release Tablets, USP 750 mg, a) 100 (NDC 62037-577-01) and b) 1000 (NDC 62037-577-10), Rx Only, Manufactured by: Watson Pharma Private Limited, Verna, Salcette Goa, Distributed by: Actavis Pharma, Inc., Parsippany, NJ
- Lots / codes
a) 1333338M, exp. date 08/2020, 1333339A, exp. date 08/2020; b) 1354471A, exp. date 02/2021
- Quantity
- a) 15,329 bottles and b) 137 bottles
- Company
- Teva Pharmaceuticals USA, Parsippany, NJ
- Distribution
- Product was distributed throughout the United States, including Puerto Rico.
- Initiated
- June 2, 2020 · Voluntary: Firm initiated
- Classified
- June 19, 2020
- Reported
- July 1, 2020
- Ended
- April 12, 2024
- How notified
- Press Release
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Recalled with it (same recall event)
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Metformin
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.